Inhibitors of fatty acid amide hydrolase

1. A compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof;

wherein:

(i) Z 1 is —OH or —OR 3 and Z 2 is —OH, or —OR 4 , an optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 2-6 heteroalkenyl, optionally substituted C 2-6 heteroalkynyl, optionally substituted C 6-10 aryl, or optionally substituted 5-10 membered heteroaryl; or

(ii) Z 1 is —OH or —OR 3 , and Z 2 and wherein the ring is comprised of carbon atoms and optionally one or more additional heteroatoms independently selected from the group consisting of N, S and O taken together form an optionally substituted 5- to 7-membered ring;

W 3 is CR 15 ;

X is a covalent bond, —O—, —N═N—, —C═N—, —NR 6 —, —C(NR 6 )—, —S—, —C(O)—, —S(O)—, —S(O) 2 , or optionally substituted C 1-6 alkylene, wherein one, two or three methylene units of the C 1-6 alkylene are optionally and independently replaced with one or more groups selected from —O—, —N═N—, —C═N—, —NR 6 —, C(NR 6 )—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

each instance of R 1 is, independently, halogen, —OR 8 , —CF 3 , —CN, —NO 2 , —SO 2 R 8 , —SOR 8 , —C(O)R 8 , —CO 2 R 8 , —C(O)N(R 8 ) 2 , —CHO, —N 3 , —N 2 R 8 , —N(R 8 ) 2 , —B(OH) 2 , optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl;

each instance of R 2 is, independently, —OR 9 , —N(R 9 ) 2 , optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or unsubstituted C 6-10 aryl;

each instance of R 3 and R 4 is, independently, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 2-6 heteroalkenyl, optionally substituted C 2-6 heteroalkynyl, optionally substituted C 6-10 aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R 6 , R 8 and R 9 is, independently, hydrogen, —SO 2 R 11 , —SOR 11 , —C(O)R 11 , —CO 2 R 11 , —C(O)N(R 11 ) 2 , —C(O)NH(R 11 ), —C(O)NH 2 , optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 2-6 heteroalkenyl, optionally substituted C 2-6 heteroalkynyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6-10 aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R 11H is, independently, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 2-6 heteroalkenyl, optionally substituted C 2-6 heteroalkynyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6-10 aryl, or optionally substituted 5-10 membered heteroaryl;

R 15 is hydrogen, halogen, —CF 3 , optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;

n is 0, 1, 2 or 3; and

with the proviso that the following compound is excluded:

2. The compound of claim 1 , wherein X is a covalent bond, —O—, or —(CH 2 )—.

3. The compound of claim 1 , wherein Z 1 and Z 2 are both OH.

4. The compound of claim 3 , wherein n is 0.

5. The compound of claim 4 , wherein R 2 is optionally substituted C 1-6 alkyl.

6. The compound of claim 5 , wherein R 2 is C 1-6 alkyl substituted with optionally substituted phenyl.

7. The compound of claim 5 , wherein R 2 is C 1-6 alkyl substituted with —CF 3 or —CF 2 CF 3 .

8. The compound of claim 5 , wherein the C 1-6 alkyl is substituted with an optionally substituted 5- or 6-membered ring having 0-4 heteroatoms selected from N, O or S.

9. The compound of claim 5 , wherein the C 1-6 alkyl is substituted with)-N(R 0 C(O)OR 0 , wherein each R 0 is independently hydrogen or C 1-6 alkyl.

10. The compound of claim 4 , wherein R 2 is unsubstituted C 6-10 aryl or optionally substituted 5 to 10 membered heteroaryl.

11. The compound of claim 1 , wherein n is 1.

12. The compound of claim 11 , wherein R 1 is a halogen or —CF 3 .

13. The compound of claim 11 , wherein R 2 is unsubstituted C 6-10 aryl.

14. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt or prodrug thereof.

15. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or prodrug thereof.

16. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or prodrug thereof.

17. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or prodrug thereof.

18. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or prodrug thereof.

19. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or prodrug thereof.

20. A compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof;

wherein:

X is a covalent bond, —O—, or —(CH 2 )—;

W 3 is CH;

Z 1 and Z 2 are both OH;

n is 0; and

R 2 is optionally substituted C 1-6 alkyl.

21. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt or prodrug thereof, of claim 1 , and a pharmaceutically acceptable excipient, medium, or carrier.